ADMS Stock: Why It Substantially Increased Today
- The stock price of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) increased by over 70% pre-market today. This is why it happened.
- 10/11/2021
|
Adamas Announces New Employment Inducement Grants
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of
- 10/08/2021
|
Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year's UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories
- 10/01/2021
|
Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society's (MDS) Congress
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FD
- 09/16/2021
|
Adamas Announces New Employment Inducement Grants
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of
- 09/10/2021
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of
- 08/13/2021
|
Adamas Pharmaceuticals, Inc. (ADMS) CEO Neil McFarlane on Q2 2021 Results - Earnings Call Transcript
- Adamas Pharmaceuticals, Inc. (ADMS) CEO Neil McFarlane on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Lags Revenue Estimates
- Adamas (ADMS) delivered earnings and revenue surprises of 0.00% and -1.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2021
|
Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announces the issuance of two patents covering GOCOVRI® (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021. These two patents are the first issued in this patent f
- 07/22/2021
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted four new employees restricted stock units to acquire 44,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of t
- 07/09/2021
|
Adamas to Present at Upcoming William Blair Biotech Focus Conference
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 1:00 pm Eastern Time. The fireside chat will be broadcast live from the investor relations sectio
- 07/08/2021
|
Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth
- Adamas Pharmaceuticals reported their Q1 earnings with a slight beat on EPS and a slight miss on revenue. GOCOVRI continues to report impressive growth despite a lackluster launch.
- 07/06/2021
|
Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options
- Investors need to pay close attention to Adamas Pharmaceuticals (ADMS) stock based on the movements in the options market lately.
- 07/02/2021
|
Adamas to Present at Upcoming SVB Leerink CNS Forum
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present “What's Happening in Parkinson's Disease & the GOCOVRI Opportunity” at the SVB Leerink CNS Forum on Tuesday, June 29th at 1:10 pm Eastern Time. The presentation will be broadcast live from the investor relations section of the Ad
- 06/23/2021
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of
- 06/11/2021
|
New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson's Disease
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, “Effects of GOCOVRI® (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson's disease and dyskinesia” in the peer-reviewed journal of Neurology and Therapy. Th
- 06/10/2021
|
Adamas to Present at Upcoming June Conferences
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the organization will be participating in two upcoming June conferences: Christopher B. Prentiss, Chief Financial Officer will present at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3 2021 at 11:00 am Eastern Time. Neil F. McFarla
- 05/27/2021
|
ADMS Stock: Over 9% Increase Intraday Explanation
- The stock price of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) increased by over 9% during intraday trading. This is why it happened.
- 05/11/2021
|
Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q1 2021 Results - Earnings Call Transcript
- Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates
- Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2021
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted five new employees restricted stock units to acquire 58,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of t
- 05/07/2021
|
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: Should You Buy?
- Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/03/2021
|
Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson's Disease and Care Partners
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the launch of “Picture More Time,” a disease education campaign focused on raising awareness and understanding of OFF time and dyskinesia and the emotional and social impacts these motor complications have on people with Parkinson's disease (PD) and their care pa
- 04/27/2021
|
Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting. One of the presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesi
- 04/15/2021
|
Adamas to Present at Upcoming Needham Conference
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 12 – 15, 2021. The fireside chat will be webcast live on April 14 from 3:00 Eastern Time on the investor relatio
- 04/07/2021
|
Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson's disease
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of an article entitled “Amantadine ER (Gocovri®) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinson's disease” in the peer-reviewed journal Frontiers in Neurology. GOCOVRI® (amantadine) extend
- 03/29/2021
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of th
- 03/05/2021
|
Strength Seen in Adamas (ADMS): Can Its 5.9% Jump Turn into More Strength?
- Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 03/02/2021
|
Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $4.40 per share. All of the shares in the offering are being sold by Adamas. The gross proceeds of the offering to Adamas, before deducting underw
- 02/24/2021
|
Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas. Adamas intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15
- 02/24/2021
|
Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q4 2020 Results - Earnings Call Transcript
- Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q4 2020 Results - Earnings Call Transcript
- 02/23/2021
|
Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates
- Adamas (ADMS) delivered earnings and revenue surprises of -20.76% and 1.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2021
|
Adamas Pharmaceuticals: Q4 Earnings Insights
- Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51).
- 02/23/2021
|
Adamas to Present at Upcoming Healthcare Conferences
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, is scheduled to present at the following investor conferences: 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 1:40 p.m. ET (10:40 a.m. PT) Cowen 41st Annual Healthcare Conference
- 02/17/2021
|
Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. Investor Conference Call and Webcast The conference call can be accessed by dialing 1-877-407-9716 for
- 02/10/2021
|
Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson's Disease Patients Experiencing OFF Episodes
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine) extended release capsules, gaining a second indication for the product. GOCOVRI is now approved as an adjunc
- 02/01/2021
|
Adamas Announces Settlement of Patent Litigation with Zydus
- EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation concerning Zydus's Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and
- 02/01/2021
|
Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021
- -- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 --
- 01/13/2021
|
Adamas to Present at Upcoming ICR Conference
- EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021.
- 01/07/2021
|
Adamas Completes Acquisition of OSMOLEX ER®
- Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition
- 01/05/2021
|
Adamas to Present at Upcoming H.C. Wainwright Conference
- EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021.
- 01/04/2021
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the company's common stock, at a per share exercise price of $4.88, the closing trading price on December 7, and restricted stock units to acquire 14,250 shares of the company's common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- 12/11/2020
|
Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners
- Amended terms will provide added flexibility to help drive the growth of the Company Amended terms will provide added flexibility to help drive the growth of the Company
- 12/02/2020
|
Adamas Announces Agreement to Settle Patent Litigation with Osmotica
- As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® As part of this agreement Adamas will acquire the global rights to OSMOLEX ER®
- 12/02/2020
|
Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg
- EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scientific leadership roles at Acadia, Cavion, Teva, Pfizer, Allergan, and Biogen. Additionally, Adamas announced the retirement of Ivan Lieberburg, MD, PhD from the Adamas board.
- 11/23/2020
|
Adamas to Present at Upcoming Piper Sandler Conference
- EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held December 1-3, 2020.
- 11/18/2020
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees the option to purchase an aggregate of 45,000 shares of the company's common stock, at a per share exercise price of $3.45, the closing trading price on November 6, and restricted stock units to acquire 22,500 shares of the company's common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- 11/13/2020
|
Adamas Pharmaceuticals: Unjustified Sell-Off Following Another Strong Quarter
- Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI. Adamas looks to have found a rhythm for GOCOVRI and the commericial numbers continue to improve. In addition,i t is now collecting royalties for NAMZARIC.
- 11/13/2020
|
Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q3 2020 Results -Earnings Call Transcript
- Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q3 2020 Results -Earnings Call Transcript
- 11/08/2020
|
Adamas Reports Third Quarter 2020 Financial Results
- Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019
- 11/05/2020
|
Adamas announces settlement agreement of previously disclosed class action litigation
- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed a Memorandum of Understanding to settle one of the previously disclosed securities class-action lawsuits, Plymouth v. Adamas Pharmaceuticals, Inc., et al., Case No. RG19018715, pending in the California Superior Court for the County of Alameda.
- 11/02/2020
|
Chrono Trigger at 25: Into the Future
- All this week, I’ve been writing a series of articles about my favorite game of all time, Chrono Trigger, as it reaches its 25th anniversary. I’ve held up the game’s story, characters, …
- 08/21/2020
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 36,000 shares of the company’s common stock, at a per share exercise price of $3.78, the closing trading price on August 7, and restricted stock units to acquire 18,000 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.Contact:Investors: Peter Vozzo Westwicke Partners 443-213-0505 peter.vozzo@westwicke.comMedia: Sarah Mathieson Vice President, Communications & Engagement 510-450-3528 smathieson@adamaspharma.com
- 08/14/2020
|
Is Adamas Stock Still Worth Buying After Its 77% Rally? This 5-Star Analyst Says ‘Yes’
- It has been hard going for long term investors of Adamas Pharmaceuticals (ADMS). The stock has been down trending since the start of 2018. However, at long last investors had something to cheer about. The Emeryville, California based micro-cap added a blistering 77% to its share price in the past 3 trading days. Adamas’ surge came off the back of a Q2 earnings beat. Adamas generated revenue of $18.79 million, almost all of which was from Gocovri, the company’s treatment for dyskinesia (the uncontrolled movements) in Parkinson patients who are taking a levodopa-based therapy.Gocovri brought in revenue of $18 million, up 24% quarter-over-quarter and up by 41% year-over-year, beating the Street’s $15.3 million estimate. Adamas also posted a beat on the bottom line, with Q2 GAAP EPS of -$0.37 ahead of consensus by $0.24.Gocovri was also responsible for the quarter’s other highlight. Along with the treatment’s excellent performance, the FDA accepted Adamas’ sNDA (supplemental new drug application) to extend Gocovri’s label to treat OFF episodes – the times when levodopa does not working perfectly - in Parkinson's disease patients receiving the therapy. A PDUFA date is set for February 1, 2021.William Blair analyst Tim Lugo argues that should the FDA approve the label extension, “the full range of benefits provided by Gocovri,” will become apparent. Overall, Lugo maintains Adamas’ value is currently going unnoticed by the market.The 5-star analyst said, “We believe the initiatives undertaken by new management who joined the company in 2019, such as the sNDA for Gocovri’s label revision and Gocovri Cares Coordinator Program, are starting to show effect. The cash balance of $103.4 million at the end of the second quarter is sufficient to get the company into 2021 and should provide sufficient runway for continued execution of Gocovri commercialization. With an enterprise value of just over $90 million and Gocovri to bring in an estimated $68.9 million in sales during the year, we believe there remains a deep value disconnect for shares.”Accordingly, Lugo rates ADMS shares an Outperform (i.e. Buy). Lugo has no fixed price target in mind. (To watch Lugo’s track record, click here)The rest of the Street, though, sees plenty of upside in the cards. With an average price target of $8.76, the analysts expect shares to surge by an additional 90% over the next 12 months. The optimistic target is extended to Adamas’ consensus rating: A Strong Buy - based on 3 Buys and 1 Hold. (See Adamas stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/12/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
Adamas Reports Second Quarter 2020 Financial Results
- Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019 Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2020, and recent corporate highlights. “Adamas delivered a strong performance this quarter, reflecting the successful execution of our growth strategy as well as our ability to rapidly adapt to the challenges posed by the ongoing pandemic,” said Neil F. McFarlane, Chief Executive Officer. “Additionally, we achieved a key milestone during the quarter with the FDA acceptance for review of our sNDA for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease patients receiving levodopa-based therapy. As we continue to respond to an uncertain environment, our focus remains on serving the patient community.”Recent highlights * GOCOVRI product sales were $18.0 million in the second quarter of 2020, an increase of 41% as compared to $12.7 million in the second quarter of 2019. * Total paid prescriptions (TRx) of GOCOVRI were approximately 8,150 in the second quarter of 2020, a 32% increase over approximately 6,160 TRx in the second quarter of 2019 and an increase of 13% over approximately 7,210 TRx in the first quarter of 2020. Strong patient persistence of 45%-50% at 12 months continued for GOCOVRI in the second quarter of 2020. * New paid prescriptions (NRx) of GOCOVRI were approximately 370 in the second quarter of 2020 compared to NRx of approximately 500 in the first quarter of 2020, reflecting a decline in patient visits to clinics due to the pandemic during the second quarter of 2020. * The Company began earning royalty revenue on net sales of NAMZARIC® beginning May 18, 2020, recognizing $0.8 million in the second quarter of 2020. Royalties will be earned quarterly through 2024. * Supplemental New Drug Application for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy was accepted for review by the U.S. Food and Drug Administration. The anticipated Prescription Drug User Fee Act action date is February 1, 2021. * The United States Patent and Trademark Office issued a new patent for GOCOVRI that covers a method of reducing OFF time and increasing good ON time in people with PD being treated with levodopa.Financial resultsRevenueTotal revenue was $18.8 million for the second quarter of 2020, consisting of GOCOVRI product sales of $18.0 million and royalty revenue earned on net sales of NAMZARIC of $0.8 million. GOCOVRI product sales were up 41% compared to $12.7 million in the same period in 2019.Research and Development (R&D) expensesR&D expenses for the second quarter of 2020 were $2.6 million, compared to $8.6 million for the same period in the prior year. R&D expenses in the second quarter of 2020 substantially relate to ongoing clinical development activities, including an open-label study which will conclude by the end of 2020 and completing the assessment of the ADS-5102 program. The decrease in R&D expenses from the prior year quarter was primarily due to the completion of the Phase 3 INROADS trial for the treatment of multiple sclerosis patients with walking impairment at the end of 2019.Selling, General and Administrative (SG&A) expensesSG&A expenses for the second quarter of 2020 were $23.2 million, compared to $25.2 million for the same period in the prior year. SG&A expenses in the second quarter of 2020 were primarily attributable to sales force costs and external spend dedicated to GOCOVRI commercialization and the related administrative support. The decrease from prior year quarter was primarily attributable to a combination of cost management activities as well as a reduced cost structure while executing in a virtual environment. Net lossNet loss was $10.6 million, or $0.37 per share, basic and diluted, for the second quarter of 2020, compared to a net loss of $24.9 million, or $0.90 per share, basic and diluted, for the second quarter of 2019. Net loss for the second quarters of 2020 and 2019 included $1.7 million and $2.9 million, respectively, in non-cash stock-based compensation expense.Cash and investmentsAs of June 30, 2020, the Company had $103.4 million of cash, cash equivalents and available-for-sale securities, compared to $132.6 million at December 31, 2019.Full year 2020 expense guidanceThe Company is updating its full year 2020 guidance for R&D and stock-based compensation expenses as set forth below: Current (as of August 6, 2020) Previous (as of May 7, 2020) R&D expenses1 $8 million -- $12 million $10 million -- $15 million SG&A expenses2 $105 million -- $115 million $105 million -- $115 million Total operating expenses3 $113 million -- $127 million $115 million -- $130 million 1Includes stock-based compensation expense of $1 million.2Includes stock-based compensation expense of $7 million.3Includes stock-based compensation expense of $8 million. Investor conference call and webcast Adamas will host a conference call and webcast today, August 6, 2020, at 4:30 p.m. ET (1:30 p.m. PT). The conference call may be accessed by dialing (833) 350-1318 (U.S./Canada) or (236) 738-2277 (international) using the ID 4795503. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for replay until November 5, 2020.About GOCOVRI®GOCOVRI® (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only medicine clinically proven to reduce both dyskinesia and OFF.Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.For more information about GOCOVRI, please visit www.GOCOVRI.com.NAMZARIC®For more information, please visit www.NAMZARIC.com.About Adamas At Adamas our vision is clear - to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.Forward-looking statements Statements contained in this press release regarding matters that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas’ expectations of its full year 2020 expenses. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas’ research, clinical, development and commercial activities relating to GOCOVRI and ADS-5102, and the regulatory and competitive environment and Adamas’ business in general, see Adamas’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2020, particularly under the caption “Risk Factors.” In addition, the impact that the current COVID-19 pandemic is having and will have on demand for GOCOVRI, and the unknown duration and severity of the COVID-19 pandemic, add additional risk and uncertainty to these forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.Contact:Investors:Media: Peter VozzoSarah Mathieson WestwickeVice President of Corporate Communications 443-213-0505510-450-3528 peter.vozzo@westwicke.comsmathieson@adamaspharma.com — Financial Tables Attached —Adamas Pharmaceuticals, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenues: Product sales$17,954 $12,691 $32,435 $24,356 Royalty revenue840 — 840 — Total revenues18,794 12,691 33,275 24,356 Costs and operating expenses: Cost of product sales381 685 953 1,098 Research and development2,550 8,598 5,015 18,812 Selling, general and administrative, net23,177 25,216 47,729 52,904 Total costs and operating expenses26,108 34,499 53,697 72,814 Loss from operations(7,314) (21,808) (20,422) (48,458) Interest and other income, net215 734 299 1,457 Interest expense(3,467) (3,797) (7,091) (7,528) Net loss$(10,566) $(24,871) $(27,214) $(54,529) Net loss per share, basic and diluted$(0.37) $(0.90) $(0.97) $(1.98) Weighted average shares used in computing net loss per share, basic and diluted28,194 27,579 28,112 27,516 Adamas Pharmaceuticals, Inc.
- 08/06/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Will Adamas Pharmaceuticals (ADMS) Report Negative Earnings Next Week? What You Should Know
- Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
- EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. Investor Conference Call and Webcast The conference call can be accessed by dialing (833) 350-1318 for participants in the U.S. or Canada and (236) 738-2277 for international callers. All callers must provide the following Conference ID: 4795503. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay until November 5, 2020.About Adamas Pharmaceuticals, Inc. At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com. ContactInvestors: Peter Vozzo Managing Director, Westwicke 443-213-0505 peter.vozzo@westwicke.comMedia: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com
- 07/23/2020
|
Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinson’s disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform
- EMERYVILLE, Calif., July 15, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to.
- 07/15/2020
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif., July 10, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted.
- 07/10/2020
|
HCR Partners Announces Two New Appointments to Senior Advisor Board
- HCR Partners Announces Two New Appointments to Senior Advisor Board
- 07/07/2020
|
Analysts' Top Healthcare Picks: Bristol Myers (BMY), Viking Therapeutics (VKTX) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bristol Myers
- 07/02/2020
|
Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from Northland Securities - Markets
- In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Aridis Pharmaceuticals (ARDS – Research
- 06/22/2020
|
Nabriva (NBRV) Gets a Buy Rating from Northland Securities - Markets
- Northland Securities analyst Carl Byrnes maintained a Buy rating on Nabriva (NBRV – Research Report) today and set a price
- 06/22/2020
|
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (NASDAQ: HRTX) and Tandem Diabetes Care (NASDAQ: TNDM) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics
- 06/22/2020
|
Xeris Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Xeris Pharmaceuticals reports positive topline data for insulin trial. Eloxx restarts cystic fibrosis study. Adamas Pharmaceuticals reports disappointing data f
- 06/20/2020
|
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * Affimed NV (NASDAQ: AFMD) (announced completion of dosing of first cohort in Phase 1/2A study of AFM24 in treating advanced EGFR-expressing solid tumors) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (announced additional data from Phase 1/2 study of investigational gene therapy for severe hemophilia A) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Cytokinetics, Inc. (NASDAQ: CYTK) * DiaMedica Therapeutics Inc (NASDAQ: DMAC) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Ideaya Biosciences Inc (NASDAQ: IDYA) * ITAMAR MED LTD/S ADR (NASDAQ: ITMR) * MannKind Corporation (NASDAQ: MNKD) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Neubase Therapeutics Inc (NASDAQ: NBSE) * NGM Biopharmaceuticals Inc (NASDAQ: NGM) * Novo Nordisk A/S (NYSE: NVO) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Odonate Therapeutics Inc (NASDAQ: ODT) * Passage Bio Inc (NASDAQ: PASG) * Quidel Corporation (NASDAQ: QDEL) * Sanofi SA (NASDAQ: SNY) (announced positive results for a Phase 3 study of its enzyme replacement therapy avalglucosidase alfa in late-onset Pompe disease) * Sarepta Therapeutics Inc (NASDAQ: SRPT) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * TELA Bio Inc (NASDAQ: TELA) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (announced orphan drug designation for tacrolimus for prophylaxis of lung allograft rejection) * Vaxcyte Inc (NASDAQ: PCVX) (went public Friday) * Zai Lab Ltd (NASDAQ: ZLAB) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 17) * BioCardia Inc (NASDAQ: BCDA) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Lantern Pharma Inc (NASDAQ: LTRN) (went public Thursday)Stocks In Focus Eloxx Resumes Midstage Cystic Fibrosis Study In Europe, Israel Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) said enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis has resumed in Israel and Europe after being temporarily paused in response to the COVID-19 pandemic.Enrollment in the U.S. trial remains paused due to safety concerns, Eloxx said. The company said it's looking to complete enrollment in its Phase 2 proof-of-concept trial and report top-line data as soon as feasible.The stock was soaring 21.31% to $3.70 premarket Thursday. Adamas Pharma Confirms Shelving Of Gocovri Study In Multiple Sclerosis Patients With Walking Impairment Adamas Pharmaceuticals Inc (NASDAQ: ADMS) said that following a comprehensive analysis of Phase 3 data from the INROADS study of ADS-5102 in multiple sclerosis patients with walking impairment, it has reconfirmed its decision not to initiate further late-stage development in MSW.The company noted that further engagement with the FDA regarding a potential path to submission confirmed the need of an additional pivotal Phase 3 confirmatory study.The stock was down 9.09% at $2.60 premarket. Emergent Bio To Invest $75M In Expansion Of CDMO Capabilities Emergent Biosolutions Inc (NYSE: EBS) said it will further strengthen its contract development and manufacturing capabilities by expanding into viral vector and gene therapy by investing $75 million in its Canton, Massachusetts facility.The facility is focused on the development and manufacturing of drug substances for live viral vaccines, including the company's smallpox vaccine.In premarket trading Thursday, the stock was up 1.76% to $71.18.Illumina Buys Cloud-Based Genomic Analysis Software Company Illumina, Inc. (NASDAQ: ILMN) announced the acquisition of Netherlands-based BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers.The deal will enhance Illumina's capabilities to analyze and interpret the data produced by its sequencing systems, the company said. See also: The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx Roche Reports Positive Results For Late-Stage Breast Cancer Study Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the Phase 3 IMpassion031 study evaluating Tecentriq in combination with chemotherapy met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of people with early triple-negative breast cancer regardless of PD-L1 expression.The study is comparing the combination to placebo plus chemotherapy. In the study, fewer patients who received the Tecentriq combination as a neoadjuvant treatment had evidence of tumor tissue detectable at the time of surgery regardless of PD-L1 expression in comparison to the control arm.Tonix Announces Expansion Of Vaccine Collaboration Agreement Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced an expansion of its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19.The research is part of an ongoing a collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix's TNX-1800, a live replicating virus vaccine designed to protect against COVID-19.The data will support the interpretation of animal trial results with TNX-1800, which are expected in the fourth quarter of 2020 and subsequent human trials.In premarket trading Thursday, Tonix shares were jumping 28.39% to 80 cents.Rexahn To Reverse Merge With Ocuphire Pharma Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) announced an agreement to merge with privately held Ocuphire Pharma in an all-stock deal. The transaction is expected to close in the second half of 2020.View more earnings on IBBFollowing the consummation of the deal, the combined company will change its name to Ocuphire Pharma Inc, and will likely to trade on the Nasdaq under the ticker symbol "OCUP."The combined company will focus on the advancement of its pipeline of ophthalmic drug candidates, Rexahn said.Hutchison Gets Fast Track Designation For Drug To Treat Colorectal Cancer HUTCHISON CHINA/S ADR (NASDAQ: HCM) said the FDA has granted Fast Track Designation for the development of fruquintinib for patients with previously treated metastatic colorectal cancer. The company said it is initiating a Phase 3 registration study, known as the FRESCO-2 study, in refractory mCRC in the U.S., Europe and Japan, with enrollment set to begin in mid-2020.Offerings Leap Therapeutics Inc (NASDAQ: LPTX) said it has commenced an underwritten public offering of its common stock and pre-funded warrants to purchase shares of its common stock.All shares of common stock and pre-funded warrants to be sold in the offering will be offered by the company.The stock slipped 15.08% to $2.14 in after-hours trading.IVERIC bio Inc (NASDAQ: ISEE) priced its upsized underwritten public offering of 24.54 million shares of its common stock at $4.10 per share and the pre-funded warrants to purchase 1.9143 million shares at $4.099 per pre-funded warrant, in each case less underwriting discounts and commissions. All of the securities are being offered by the company.The stock was down 2.03% at $4.35 premarket. IDEAYA, which recently announced an oncology collaboration, priced an underwritten public offering of 6.67 million shares at $15 per share to generate gross proceeds of $100 million. The offering is expected to close on or about June 22.The stock fell was down 9.42% at $16.82 premarket Thursday.Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) announced a common stock offering, with all the shares earmarked for the offering sold by the company.The stock was down 0.33% at $4.49 premarket. Orthopediatrics Corp (NASDAQ: KIDS) said it is commencing an underwritten public offering of its common stock.The stock was down 3.06% at $48.15 premarket. On The Radar PDUFA Dates Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and its Japanese partner Kyowa Kirin have a tryst with the FDA, as the agency is set to rule on hypophosphatemia treatment candidate burosumab.The regulatory agency will also decide on Epizyme Inc's (NASDAQ: EPZM) regulatory application for label expansion for tazemetostat, this time for follicular lymphoma.Earnings * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Urovant Sciences Ltd (NASDAQ: UROV) (after the close)Related Link: Sinovac Makes Headway In Coronavirus Vaccine Race With Positive Preliminary Phase 1/2 Results See more from Benzinga * The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/18/2020
|
Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment
- Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of ADS-5102 in multiple sclerosis patients with walking impairment (MSW). A comprehensive analysis of the INROADS Phase 3 data validated the top line results announced in December 2019 and informed a revised target product profile reflecting the scale of clinical benefit observed in the study. Additional patient, physician, and payer research based on the revised profile projected a limited commercial opportunity.
- 06/17/2020
|
Northland Securities Reaffirms Their Buy Rating on vTv Therapeutics (VTVT) - Markets
- In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on vTv Therapeutics (VTVT – Research
- 06/15/2020
|
Analysts Offer Insights on Healthcare Companies: NuVasive (NASDAQ: NUVA), Sarepta Therapeutics (NASDAQ: SRPT) and Bluebird Bio (NASDAQ: BLUE) - Markets
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on NuVasive (NUVA – Research Report),
- 06/12/2020
|
Acadian Asset Management LLC Takes Position in Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
- Acadian Asset Management LLC purchased a new stake in Adamas Pharmaceuticals Inc (NASDAQ:ADMS) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 18,183 shares of the specialty pharmaceutical company’s stock, valued at approximately $53,000. Acadian Asset Management LLC owned 0.06% of Adamas […]
- 06/10/2020
|
33 Stocks Moving in Monday's Pre-Market Session
|
102 Biggest Movers From Friday
|
75 Stocks Moving In Friday's Mid-Day Session
|
The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * argenx SE - ADR (NASDAQ: ARGX) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Imara Inc (NASDAQ: IMRA) * Inari Medical Inc (NASDAQ: NARI) * Intellia Therapeutics Inc (NASDAQ: NTLA) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Passage Bio Inc (NASDAQ: PASG) * Qiagen NV (NYSE: QGEN) * Replimune Group Inc (NASDAQ: REPL) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) * Evofem Biosciences Inc (NASDAQ: EVFM)(priced its 28.5 million common stock offering) * Iterum Therapeutics PLC (NASDAQ: ITRM)Stocks In Focus Adamas' Regulatory Application For Label Expansion For Parkinson's Drug Accepted For Review Adamas Pharmaceuticals Inc (NASDAQ: ADMS) said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy. The company said the anticipated PDUFA action date is Feb. 1, 2021.Gocovri has already been approved for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.The stock rallied 18.56% to $3.13 in after-hours trading.Oxford Immunotech Approached With $400M Bid Medical diagnostics company Oxford Immunotec Global PLC (NASDAQ: OXFD) is being approached with a $15 per share or a $400 million offer by a consortium of private equity investors led by KKR and Ampersand Capital Partners, Reuters reported.The company had apparently approached several health care peers in the past year but was unsuccessful in striking a deal.The stock climbed 15.74% to $15 in after-hours trading.Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA DatesAbbVie Forges Partnerships With 3 Institutions For Developing COVID-19 Antibody Treatment AbbVie Inc (NYSE: ABBV) announced a collaboration with Harbour BioMed, Utrecht University and Erasmus Medical Center to develop a novel antibody therapeutics to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.The collaboration plans to study the fully human, neutralizing antibody 47D11 discovered by institutions that targets the conserved domain of the spike protein of SARS-CoV-2.AbbVie will support preclinical activities, while also preparing for later stage preclinical and clinical development work. The company has received an exclusive option for licensing the candidate.Merck Gets FDA Approval For Triple-combo Antibiotic To Treat Hospital-Acquired Pneumonia Merck & Co., Inc. (NYSE: MRK) announced FDA approval of its Recarbrio - a triplet combination of imipenem-cilastatin and relebactam - to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older.Novartis Announces Positive Results For Asthma Study Novartis AG (NYSE: NVS) announced publication of full results from the Phase 3b ARGON study in Respiratory Medicine, which showed once-daily treatment with single inhaler, high- and medium-dose Enerzair Breezhaler demonstrated non-inferiority to a free combination of twice-daily, high-dose salmeterol xinafoate/fluticasone propionate, plus once-daily tiotropium, delivered in two different devices, in improving quality of life in people with uncontrolled asthma.Among secondary analyses, improvements in lung function, asthma control, health status, and reductions in moderate exacerbations were observed with high-dose once-daily IND/GLY/MF compared to high-dose Sal/Flu plus Tio, the company said.PDS Biotech To Evaluate Lead Asset In Mid-Stage Study In Cervical Cancer PDS Biotechnology Corp (NASDAQ: PDSB) announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101, in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer.PDS101, according to the company, is being developed for multiple cancers associated with HPV infection, including anal, cervical and head and neck cancers. Results of a Phase 1 trial released in Sept. 2019 showed the investigational asset demonstrated potent in vivo induction of active killer T-cells that target cancer cells containing the cancer-causing HPV proteins, as well as an excellent safety profile with no limiting toxicities.Offerings Menlo Therapeutics Inc (NASDAQ: MNLO) said it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offeringThe stock slipped 14.03% to $1.90 in after-hours trading.On The Radar IPOs Applied Molecular Transport, a clinical-stage biopharma, priced its upsized initial public offering, or IPO, of 11 million shares at $14 per share compared to the initially estimated range of $12-$14. The shares will begin trading on the Nasdaq under the ticker symbol AMTI.Stockholm, Sweden-based specialty pharma company Calliditas Therapeutics priced its IPO of 9.231 million shares, consisting of a public offering of 8.317 million ADSs, with each ADSs representing two common shares, and a concurrent private placement of 924,000 common shares to certain qualified investors in Europe and certain other jurisdictions outside of the U.S. The company expects to raise gross proceeds of $90 million from the offering. The offering was upsized from the initial plan of an offering worth $75 million. The shares will commence trading on the Nasdaq under the ticker symbol CALT.See more from Benzinga * The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic * Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics * The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/05/2020
|
40 Stocks Moving in Friday's Pre-Market Session
|
The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 4)
Biohaven Pharmaceutical...
- 06/05/2020
|
Adamas Announces FDA Filing Acceptance Of sNDA To Modify The Indication Statement For GOCOVRI To Include Treatment For Parkinson's Disease Patients Receiving Levodopa And Experiencing OFF Episodes
|
Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes
- Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy has been accepted for review by the U.S. Food and Drug Administration (FDA). GOCOVRI (amantadine) extended release capsules is approved to treat dyskinesia in PD patients treated with levodopa-based therapy, with or without other dopaminergic medications.
- 06/04/2020
|
Adamas to Present at Upcoming William Blair Conference
- EMERYVILLE, Calif., June 03, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful.
- 06/03/2020
|
Quelles montres de luxe d’occasion acheter en ligne actuellement?
- SÉLECTION - Quelles montres signées de grandes marques voient leur cote progresser sur le Net? Le site spécialisé de vente en ligne Chrono 24 dresse le Top 5 de celles dont la valeur augmente.
- 06/03/2020
|
Edited Transcript of ADMS earnings conference call or presentation 7-May-20 9:00pm GMT
- Q1 2020 Adamas Pharmaceuticals Inc Earnings Call
- 05/21/2020
|
Intuit (INTU) to Report Q3 Earnings: What's in the Cards?
|
Adamas Announces Issuance Of New US Patent For Gocovri In Parkinson's Disease, Expands Coverage With Reduction Of 'Off' Time And Increased 'Good ON' Time
|
Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time
- Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI® (amantadine) extended release capsules. The new patent covers a method of reducing ‘OFF’ time and increasing ‘good ON’ time (ON time without troublesome dyskinesia) in people with Parkinson’s disease (PD) being treated with levodopa. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
- 05/13/2020
|
Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson's disease - expands ...
|
96 Biggest Movers From Friday
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif., May 08, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five.
- 05/08/2020
|
70 Stocks Moving In Friday's Mid-Day Session
|
Adamas Announces New Employment Inducement Grant
|
Adamas Pharmaceuticals Q1 EPS $(0.590) Beats $(0.790) Estimate, Sales $14.481M Miss $15.360M Estimate
|
Adamas Reports First Quarter 2020 Financial Results
- First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter.
- 05/07/2020
|
China April rare earth exports fall as coronavirus threatens global demand
- China's rare earth exports fell 22.2% month-on-month in April, customs data showed on Thursday, easing from a spike in March that saw ports clear shipments held up by coronavirus-related curbs on transport and as the pandemic hits overseas demand.
- 05/07/2020
|
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q1 2020 Results - Earnings Call Transcript
- Start Time: 16:30 End Time: 17:13 ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2020 Earnings Conference Call May 06, 2020, 16:30 PM ET Company Participants Adam Grossm
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
EchoStar (SATS) to Report Q1 Earnings: What's in the Offing?
|
A10 Networks (ATEN) to Report Q1 Earnings: What's in Store?
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
|
The Michael J. Fox Foundation Releases New Video Resource to Empower Patients and Families to Participate in Critical Parkinson's Research
- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has released a new video, "Together, We Can Solve the Parkinson's Puzzle," to illustrate the role each individual within a family and community can play to help scientists piece together a fuller picture of Parkinson'
- 04/29/2020
|
All You Need to Know About Adamas (ADMS) Rating Upgrade to Buy
- Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 04/28/2020
|
Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
- EMERYVILLE, Calif., April 27, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday,.
- 04/27/2020
|
Adamas Announces New Employment Inducement Grant
- EMERYVILLE, Calif., April 10, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted.
- 04/10/2020
|
Macquarie Group Ltd. Sells 93,262 Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
- Macquarie Group Ltd. trimmed its stake in shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 4.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,167,416 shares of the specialty pharmaceutical company’s stock after selling 93,262 shares during the quarter. […]
- 04/07/2020
|
William Blair Maintains a Buy Rating on Biohaven Pharmaceutical Holding Co (BHVN)
- William Blair analyst Tim Lugo maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN) on March 23. The company's shares closed last Monday
- 03/27/2020
|
William Blair Maintains a Buy Rating on Biohaven Pharmaceutical Holding Co (BHVN)
- William Blair analyst Tim Lugo maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report) on March
- 03/27/2020
|
Adamas Pharmaceuticals Stock – Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors – ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.
- PHILADELPHIA, March 23, 2020 -- Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS).
- 03/23/2020
|
Adamas Pharmaceuticals Stock – Kehoe Law Firm, P.C. ...
|
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
- Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
- 03/20/2020
|
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
- Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.
- 03/20/2020
|
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
Stocks That Hit 52-Week Lows On Wednesday
- During Wednesday's morning session, 690 stocks hit new 52-week lows.
Intriguing Points:
Boeing (NYSE: BA) was the biggest company on a market cap basis to set a new...
- 03/11/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
- 03/11/2020
|
Edited Transcript of ADMS earnings conference call or presentation 25-Feb-20 9:30pm GMT
- Q4 2019 Adamas Pharmaceuticals Inc Earnings Call
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
Adamas Announces New Employment Inducement Grant
|
Earnings Update: Here's Why Analysts Just Lifted Their Adamas Pharmaceuticals, Inc. Price Target To US$12.69
- There's been a major selloff in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) shares in the week since it released its...
- 02/28/2020
|
Adamas Reports Fourth Quarter and Full Year 2019 Financial Results
- - Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018;total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI®.
- 02/25/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Co-Diagnostics Inc (NASDAQ: CODX )(received CE mark for its coronavirus test) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) Gilead Sciences, Inc. (NASDAQ: GILD )(reacted to a statement from WHO that its experimental drug remdesivir could be the one drug that may have efficacy) NGM Biopharmaceuticals Inc (NASDAQ: NGM )( reacted to positive readout for its NASH drug) PAVmed Inc (NASDAQ: PAVM ) TELA Bio Inc (NASDAQ: TELA ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 24) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) AngioDynamics, Inc. (NASDAQ: ANGO ) BioSig Technologies Inc (NASDAQ: BSGM ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc.
- 02/25/2020
|
Adamas Pharmaceuticals Q4 EPS $(0.83) Beats $(0.85) Estimate, Sales $16.348M Beat $15.81M Estimate
|
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
- Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
- 02/24/2020
|
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
- Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
- 02/24/2020
|
Stonepine Capital Management, LLC Buys Affimed NV, Amarin Corp PLC, Adamas Pharmaceuticals Inc, ...
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
- Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
- 02/23/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
|
Adamas to Present at Upcoming Healthcare Conferences
- EMERYVILLE, Calif., Feb. 20, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful.
- 02/20/2020
|
Adamas to Present at Upcoming Healthcare Conferences
|
Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020
- EMERYVILLE, Calif., Feb. 19, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday,.
- 02/19/2020
|
Adamas to Announce Fourth Quarter —…–9 Financial Results and Host Conference Call on ...
|
Healthcare Value Capital, LLC Buys Antares Pharma Inc, Foamix Pharmaceuticals, Sells Walgreens ...
|
Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
- Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules for the treatment of dyskinesia in people with Parkinson's disease (PD) receiving levodopa-based therapy at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress (PAS-MDS), February 14-16, 2020 in Miami, Florida. “The data presented at this year’s MDS-PAS conference build upon the growing evidence that GOCOVRI can help improve good ON time in patients with PD who experience levodopa-induced dyskinesia,” said Jean Hubble, Vice President, Medical Affairs at Adamas.
- 02/13/2020
|
Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 'rd Pan American ...
|
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …
- 02/12/2020
|
Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease
- Adamas Pharmaceuticals, Inc. (ADMS) a company dedicated to developing and delivering medicines that make a clinically meaningful difference for people affected by neurological diseases, today announced the publication of final results from a two-year open-label study in Parkinson’s disease (PD) that demonstrated a sustained improvement in levodopa-induced dyskinesia (LID) among patients using GOCOVRI® (amantadine) extended-release capsules. The trial enrolled 223 patients, and results demonstrated that the treatment effect of GOCOVRI on motor complications (dyskinesia and OFF), as measured by the Movement Disorder Society‐Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS), Part IV, was maintained for at least two years.
- 02/11/2020
|
Adamas Pharma Highlights Publication Of 2-Year Phase 3 Open-Label EASE LID 2 Trial Of GOCOVRI For Dyskinesia In Patients With Parkinson's Disease
|
SHAREHOLDER ALERT: ADMS GDOT BYND: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / February 10, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...
- 02/10/2020
|
ADMS FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS
- NEW YORK, Feb. 10, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August.
- 02/10/2020
|
FINAL DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020
- This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) managed care's acceptance of GOCOVRI; (2) the breadth of insurer coverage for GOCOVRI prescriptions; and (3) the impact of the Company's commercialization efforts.
- 02/10/2020
|
ADMS FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. ...
|
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Collegium Pharmaceutical (COLL)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and Collegium Pharmaceutical (COLL)
- 02/07/2020
|
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Collegium Pharmaceutical (NASDAQ: COLL)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (
ALNY
–
Research Report
) and Collegium Pharmaceutical (
COLL
–
Research Report
) with bullish sentiments.
Alnylam Pharma (ALNY)
In a repor
- 02/07/2020
|
DEADLINE ALERT - Adamas Pharmaceuticals, Inc. ...
|
ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ...
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas ...
|
DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged
- 02/03/2020
|
DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. ...
|
ADMS FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. ...
|
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas ...
|
ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ...
|
DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged
- 01/27/2020
|
70 Biggest Movers From Friday
- Gainers
NanoViricides Inc (NYSE: NNVC) shares rose 54.5% to close at $8.45 on Friday after gaining 43.2% on Thursday.
SAExploration Holdings Inc (NASDAQ: SAEX) shares jumped 33%...
- 01/27/2020
|
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas ...
|
INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With ...
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas ...
|
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas ...
|
DEADLINE ALERT for HEXO, XYF, BZUN, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged
- 01/21/2020
|
ADMS INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. ...
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas ...
|
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ...
|
54 Biggest Movers From Yesterday
|
40 Stocks Moving In Wednesday's Mid-Day Session
|
Adamas Announces Settlement of Patent Litigation with Sandoz Inc.; Co. Grants Sandoz License For Its Generic Version Of GOCOVRI
|
36 Healthcare Stocks Moving In Thursday's Pre-Market Session
|
40 Stocks Moving In Wednesday's Mid-Day Session
|
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; ImmunoGen Shares Spike Higher
|
Adamas Pharmaceuticals: INROADS Data Will Make Or Break 2019
|
Adamas Pharmaceuticals (ADMS) Investor Presentation - Slideshow
|
26 Stocks Moving in Wednesday's Pre-Market Session
|
Adamas Pharmaceuticals Inc Files For Common Stock Offering Of Up To $50M
|
Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
|
80 Biggest Movers From Friday
|
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
|
Adamas Pharmaceuticals Q3 EPS $(0.99) Misses $(0.89) Estimate, Sales $13.933M Miss $14.07M Estimate
|
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
Key events next week - healthcare
|
58 Biggest Movers From Friday
|
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …
- 10/11/2019
|
Stocks That Hit 52-Week Lows On Thursday
|
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
- 10/10/2019
|
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
- The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 8.) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Albireo Pharma Inc (NASDAQ: ALBO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BIOLASE Inc (NASDAQ: BIOL ) BioTelemetry Inc (NASDAQ: BEAT ) CELYAD SA/ADR (NASDAQ: CYAD ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Clovis Oncology Inc (NASDAQ: CLVS ) (Goldman reiterated a Sell rating on the stock and cut the price target from $13 to $3.) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Endologix, Inc.
- 10/09/2019
|
42 Biggest Movers From Yesterday
|
Adamas Announces New Employment Inducement Grant
|
45 Biggest Movers From Friday
|
The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Neuralstem, Inc. (NASDAQ: CUR ) Obseva SA (NASDAQ: OBSV ) Onconova Therapeutics Inc (NASDAQ: ONTX ) RA Medical Systems Inc (NYSE: RMED ) Sierra Oncology Inc (NASDAQ: SRRA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Trinity Biotech plc (NASDAQ: TRIB ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Arbutus Halts Hepatitis B Drug Study Arbutus Biopharma Corp (NASDAQ: ABUS ) decided to discontinue the development of AB-506, an oral capsid inhibitor, which was being evaluated in a Phase 1a/1b trial for the treatment …
- 10/04/2019
|
Stocks That Hit 52-Week Lows On Thursday
|
52 Biggest Movers From Yesterday
|
58 Biggest Movers From Yesterday
|
31 Stocks Moving In Monday's Mid-Day Session
|
Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference
|
Adamas Announces New Safety And Efficacy Data For GOCOVRI In Parkinson's Disease Patients With Dyskinesia At Movement Disorder Society 2019 International Congress
|
Buy Bellus Health Before It Hits The Nasdaq
|
